
Officials with AstraZeneca recently announced that the FDA has expanded the indication of its 80/4.5 mcg budesonide and formoterol fumarate dihydrate inhalation aerosol (Symbicort), approving the drug for the treatment of asthma in patients aged 6 to 12 years.